Form 4: Black Diamond Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Kapil Dhingra acquired 30,550 stock options in Black Diamond Therapeutics on June 6, 2024.
Summary
- Kapil Dhingra, a director of Black Diamond Therapeutics, acquired 30,550 stock options on June 6, 2024.
- The exercise price of these options is $4.65.
- The options vest fully on the earlier of June 6, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
- The options expire on June 5, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of options by a director is generally viewed as a positive, but it's a routine filing.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon continued service, suggesting an expectation of ongoing involvement by the director.
Industry Context
Form 4 filings are standard disclosures for insiders, providing transparency into their transactions in the company's securities.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Director Kapil Dhingra acquired stock options. |
| 06/06/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 06/05/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.